A Phase 3 interventional study of Tavapadon and Placebo in Parkinson Disease, sponsored by AbbVie. Completed at 146 sites in 14 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.
Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 3rd largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 8th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2020.
This study's enrollment of 507 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 57 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 3 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
44 studies in Parkinson Disease by AbbVie: 5 open now, 8 under way, none of them phase 3. Of 34 finished, 18 (53%) have results posted.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2020, is one of 16 in phase 3, and was the 29th registered.
AbbVie’s Parkinson Disease studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing tavapadon in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 44 in Parkinson Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a tavapadon tablet titrated 5 to 15milligrams (mg) once daily (QD)orally for 27 weeks.
Drug: Tavapadon
Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
Drug: Placebo
Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
Also known as: PF-06649751, CVL-751
Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)
The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at endpoint.
Time frame: Week 26
Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)
The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at endpoint.
Time frame: Week 26
Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)
The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at different time points.
Time frame: Week 2, 5, 8, 11, 14, 18, 22, and 26
Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)
The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at different time points.
Time frame: Week 2, 5, 8, 11, 14, 18, 22, and 26
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III Individual Score
The MDS-UPDRS rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome.
Time frame: Week 26
In this Phase 3, Double-Blind study, a total of 368 subjects with Parkinson's Disease(PD) were be randomized in a 1:1 ratio to receive Tavapadon (5 mg to 15 mg) or Placebo once daily (QD) for 27 Weeks.
| Milestone | Placebo | Tavapadon |
|---|---|---|
| Started | 255 | 252 |
| Completed | 206 | 159 |
| Not completed | 49 | 93 |
| Withdrew: Adverse event | 23 | 43 |
| Withdrew: Lack of efficacy | 5 | 2 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Failure to meet continuation criteria | 0 | 1 |
| Withdrew: Treatment with prohibited concomitant medications | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Site terminated by sponsor | 3 | 5 |
| Withdrew: Withdrawal by subject | 12 | 33 |
| Withdrew: Other | 2 | 2 |
The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at endpoint.
| hours | Placebo | Tavapadon |
|---|---|---|
| Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary) | 0.619 ± 0.188 | 1.721 ± 0.207 |
The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at endpoint.
| hours | Placebo | Tavapadon |
|---|---|---|
| Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary) | -0.933 ± 0.182 | -1.876 ± 0.200 |
The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at different time points.
| hours | Placebo | Tavapadon |
|---|---|---|
| Week 2 | 0.535 ± 0.133 | 0.305 ± 0.133 |
| Week 5 | 0.516 ± 0.148 | 0.616 ± 0.151 |
| Week 8 | 0.470 ± 0.162 | 1.052 ± 0.168 |
| Week 11 | 0.705 ± 0.163 | 1.063 ± 0.171 |
| Week 14 | 0.584 ± 0.175 | 1.282 ± 0.187 |
| Week 18 | 0.623 ± 0.174 | 1.592 ± 0.185 |
| Week 22 | 0.870 ± 0.177 | 1.749 ± 0.190 |
| Week 26 | 0.619 ± 0.188 | 1.721 ± 0.207 |
The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at different time points.
| hours | Placebo | Tavapadon |
|---|---|---|
| Week 2 | -0.598 ± 0.127 | -0.490 ± 0.127 |
| Week 5 | -0.612 ± 0.144 | -0.849 ± 0.146 |
| Week 8 | -0.549 ± 0.153 | -1.367 ± 0.159 |
| Week 11 | -0.876 ± 0.156 | -1.629 ± 0.164 |
| Week 14 | -0.779 ± 0.173 | -1.682 ± 0.185 |
| Week 18 | -0.786 ± 0.176 | -1.810 ± 0.187 |
| Week 22 | -1.014 ± 0.179 | -1.993 ± 0.191 |
| Week 26 | -0.933 ± 0.182 | -1.876 ± 0.200 |
The MDS-UPDRS rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome.
| units on a scale | Placebo | Tavapadon |
|---|---|---|
| Part I | 0.0 ± 0.27 | 0.4 ± 0.30 |
| Part II | -0.1 ± 0.35 | -1.4 ± 0.39 |
| Part III | -4.6 ± 0.65 | -7.0 ± 0.71 |
Collected over All-cause mortality were reported from enrollment to the end of study, median time on follow up (median time subjects were followed) was 190 and 189 days for Placebo and Tavapadon, respectively. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 4 weeks after the last dose of study drug; mean duration on study drug was 169.6 and 151.7 days for Placebo and Tavapadon, respectively.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/255 (0%) | 14/255 (5.5%) | 90/255 (35.3%) |
| Tavapadon | 1/252 (0.4%) | 17/252 (6.7%) | 130/252 (51.6%) |
| Event | Placebo | Tavapadon |
|---|---|---|
| FALLInjury, poisoning and procedural complications | 0/255 | 3/252 |
| ABDOMINAL PAINGastrointestinal disorders | 0/255 | 2/252 |
| COVID-19Infections and infestations | 2/255 | 0/252 |
| ANGINA PECTORISCardiac disorders | 0/255 | 1/252 |
| CARDIAC FAILURE CHRONICCardiac disorders | 0/255 | 1/252 |
| GLAUCOMAEye disorders | 0/255 | 1/252 |
| DIARRHOEAGastrointestinal disorders | 0/255 | 1/252 |
| BRONCHITIS BACTERIALInfections and infestations | 0/255 | 1/252 |
| COVID-19 PNEUMONIAInfections and infestations | 0/255 | 1/252 |
| INFECTIVE ANEURYSMInfections and infestations | 0/255 | 1/252 |
| Event | Placebo | Tavapadon |
|---|---|---|
| NAUSEAGastrointestinal disorders | 11/255 | 36/252 |
| DYSKINESIANervous system disorders | 4/255 | 25/252 |
| DIZZINESSNervous system disorders | 8/255 | 18/252 |
| HEADACHENervous system disorders | 7/255 | 17/252 |
| ORTHOSTATIC HYPOTENSIONVascular disorders | 3/255 | 15/252 |
| COVID-19Infections and infestations | 7/255 | 13/252 |
| FALLInjury, poisoning and procedural complications | 13/255 | 13/252 |
| SOMNOLENCENervous system disorders | 11/255 | 13/252 |
| HALLUCINATION, VISUALPsychiatric disorders | 3/255 | 13/252 |
| FATIGUEGeneral disorders | 11/255 | 10/252 |
Includes all enrolled subjects that received at least one dose of study drug.
| Age, Continuous(years) | Placebo | Tavapadon | Total |
|---|---|---|---|
| Mean | 64.1 ± 8.52 | 65.6 ± 8.42 | 64.9 ± 8.49 |
| Sex: Female, Male(Participants) | Placebo | Tavapadon | Total |
|---|---|---|---|
| Female | 85 | 101 | 186 |
| Male | 170 | 151 | 321 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tavapadon | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 11 | 27 |
| Not Hispanic or Latino | 232 | 226 | 458 |
| Unknown or Not Reported | 7 | 15 | 22 |
| Race (NIH/OMB)(Participants) | Placebo | Tavapadon | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 245 | 246 | 491 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| ON Time (hours) Without Troublesome Dyskinesia at Baseline(hours) | Placebo | Tavapadon | Total |
|---|---|---|---|
| Mean | 10.148 ± 2.637 | 9.884 ± 2.569 | 10.016 ± 2.604 |
| OFF Time (hours) at Baseline(hours) | Placebo | Tavapadon | Total |
|---|---|---|---|
| Mean | 5.408 ± 2.484 | 5.638 ± 2.246 | 5.523 ± 2.369 |
| Movement Disorder Society - Unified Parkinson's Disease Rating Score at Baseline (Parts I, II, III)(units on a scale) | Placebo | Tavapadon | Total |
|---|---|---|---|
| Part I | 7.5 ± 4.93 | 8.0 ± 5.13 | 7.7 ± 5.03 |
| Part II | 12.5 ± 7.05 | 13.3 ± 6.54 | 12.9 ± 6.80 |
| Part III | 32.4 ± 14.26 | 32.6 ± 14.34 | 32.5 ± 14.29 |
Showing the first 100 of 146 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in Jan 2024, 40 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion. A results delay was requested in Dec 2024.
Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 40 months is above that.
Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tavapadon